## Biotechnology/Chemical/Pharmaceutical Customer Partnership Meeting

## September 7, 2023, 10:00 a.m. – 5:00 p.m. ET

## Clara Barton Auditorium and webinar

## **Unite d States Patent and Trademark Office**

10:00-10:15 a.m.	Welcome and opening remarks	Vaishali Udupa, Commissioner for Patents
10:15-10:30 a.m.	Summary of Amgen v. Sanofi 143 S.Ct. 1243 (2023)	Andrea Grossman, Legal Advisor- Office of Patent Legal Administration
10:30-11:00 a.m.	Enablement: The U.S. Supreme Court speaks	Duane C. Marks, Associate Vice President- Assistant General Patent Counsel, Eli Lilly and Company
11:00-11:05 a.m.	Break	
11:05-12:00 p.m.	Section 112(a)- Beyond <i>Amgen v. Sanofi</i>	Joshua E. Ney, Partner- Barnes & Thornburg LLP
12:05-1:05 p.m.	Lunch	
1:05-1:45 p.m.	Panel discussion of 35 U.S.C. 112(a)	Duane C. Marks, Associate Vice President- Assistant General Patent Counsel, Eli Lilly and Company
		Joshua E. Ney, Partner-Barnes & Thornburg LLP
		Daniel E. Kolker, Supervisory Patent Examiner
		Anne Gussow, Management Quality Assurance Specialist
		Jeffrey Lundgren, Supervisory Patent Examiner
1:45-2:45 p.m.	Patent Center and DOCX	Richard Fernandez, eMod Project Manager Office of Information Technology for Patents
2:45-2:55 p.m.	Break	
2:55-3:40 p.m.	Best practices to help growth stage companies build their IP Portfolio	Julia Kim, Patent Attorney- In Vivo Patent Law
3:40-4:30 p.m.	The Central Reexamination Unit (CRU): Reexamination, Reissue & Supplemental Examination	Jean Witz, Supervisory Patent Reexamination Specialist
4:30-4:50 p.m.	Common Sequence Compliance Errors	Christopher Babic, Supervisory Patent Examiner
4:50-5:00 p.m.	Closing remarks	Daniel Sullivan, Technology Center Director- TC 1600